Stifel Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $30

Stifel analyst Laura Prendergast maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $48 to $30.